RESUMEN
BACKGROUND: Dysbiosis or imbalance of gut microbiota in Alzheimer's disease (AD) affects the production of short-chain fatty acids (SCFAs), whereas exogenous SCFAs supplementation exacerbates brain Aß burden in APP/PS1 mice. Bifidobacterium is the main producer of SCFAs in the gut flora, but oral administration of Bifidobacterium is ineffective due to strong acids and bile salts in the gastrointestinal tract. Therefore, regulating the levels of SCFAs in the gut is of great significance for AD treatment. METHODS: We investigated the feasibility of intranasal delivery of MSNs-Bifidobacterium (MSNs-Bi) to the gut and their effect on behavior and brain pathology in APP/PS1 mice. RESULTS: Mesoporous silica nanospheres (MSNs) were efficiently immobilized on the surface of Bifidobacterium. After intranasal administration, fluorescence imaging of MSNs-Bi in the abdominal cavity and gastrointestinal tract revealed that intranasally delivered MSNs-Bi could be transported through the brain to the peripheral intestine. Intranasal administration of MSNs-Bi not only inhibited intestinal inflammation and reduced brain Aß burden but also improved olfactory sensitivity in APP/PS1 mice. CONCLUSIONS: These findings suggested that restoring the balance of the gut microbiome contributes to ameliorating cognitive impairment in AD, and that intranasal administration of MSNs-Bi may be an effective therapeutic strategy for the prevention of AD and intestinal disease.
Asunto(s)
Enfermedad de Alzheimer , Nanopartículas , Trastornos del Olfato , Enfermedad de Alzheimer/patología , Péptidos beta-Amiloides/metabolismo , Animales , Bifidobacterium/metabolismo , Ácidos y Sales Biliares , Encéfalo/metabolismo , Modelos Animales de Enfermedad , Ácidos Grasos Volátiles , Ratones , Ratones Transgénicos , Trastornos del Olfato/patología , Dióxido de SilicioRESUMEN
PURPOSE: Taste and smell disturbances in patients affected by cancer are very common, but often under-recognized symptoms. If not addressed properly, they may impact nutritional status, food enjoyment, and quality of life. Treatment tools available for clinicians to manage chemosensory alterations are limited and are often based on personal clinical experiences. The aim of this study was to assess current oncological and palliative care literature through a scoping review, in order to identify available treatments for taste and smell alterations in cancer patients. METHODS: Medline, Embase, CINAHL, ProQuest Dissertations and Theses, and Google Scholar were searched from inception until January 2020, with subject headings relevant to the domains of chemosensory alterations, palliative, and cancer care. A total of 10,718 English and French language publications were reviewed, yielding 43 articles on the researched topic. RESULTS: The heterogeneity of selected articles led to difficulties in interpretation and analysis of the available evidence. Included publications differed in study design, population sample, anticancer treatments, and measures of assessment for taste and smell disturbances. A broad variety of treatment options were described including zinc and polaprezinc, radio-protectors, vitamins and supplements, anti-xerostomia agents, active swallowing exercises, nutritional interventions, delta-9-tetrahydrocannabinol, and photobiomodulation. CONCLUSION: This scoping review identifies the current state of knowledge regarding chemosensory alterations within supportive cancer care. Despite not reaching firm conclusions, this article offers therapeutic venues to further explore in larger and more methodologically sound studies.
Asunto(s)
Trastornos del Olfato/tratamiento farmacológico , Olfato/fisiología , Trastornos del Gusto/tratamiento farmacológico , Gusto/fisiología , Adulto , Amifostina/uso terapéutico , Carnosina/análogos & derivados , Carnosina/uso terapéutico , Dronabinol/uso terapéutico , Humanos , Neoplasias/tratamiento farmacológico , Estado Nutricional/fisiología , Trastornos del Olfato/patología , Compuestos Organometálicos/uso terapéutico , Cuidados Paliativos/métodos , Calidad de Vida/psicología , Selenio/uso terapéutico , Trastornos del Gusto/patología , Compuestos de Zinc/uso terapéuticoRESUMEN
COVID-19 rapidly turned to a global pandemic posing lethal threats to overwhelming health care capabilities, despite its relatively low mortality rate. The clinical respiratory symptoms include dry cough, fever, anosmia, breathing difficulties, and subsequent respiratory failure. No known cure is available for COVID-19. Apart from the anti-viral strategy, the supports of immune effectors and modulation of immunosuppressive mechanisms is the rationale immunomodulation approach in COVID-19 management. Diet and nutrition are essential for healthy immunity. However, a group of micronutrients plays a dominant role in immunomodulation. The deficiency of most nutrients increases the individual susceptibility to virus infection with a tendency for severe clinical presentation. Despite a shred of evidence, the supplementation of a single nutrient is not promising in the general population. Individuals at high-risk for specific nutrient deficiencies likely benefit from supplementation. The individual dietary and nutritional status assessments are critical for determining the comprehensive actions in COVID-19.
Asunto(s)
Betacoronavirus/patogenicidad , Infecciones por Coronavirus/dietoterapia , Tos/dietoterapia , Factores Inmunológicos/uso terapéutico , Micronutrientes/uso terapéutico , Pandemias , Neumonía Viral/dietoterapia , Betacoronavirus/efectos de los fármacos , Betacoronavirus/inmunología , COVID-19 , Infecciones por Coronavirus/diagnóstico , Infecciones por Coronavirus/inmunología , Infecciones por Coronavirus/patología , Tos/diagnóstico , Tos/inmunología , Tos/patología , Manejo de la Enfermedad , Fiebre/diagnóstico , Fiebre/dietoterapia , Fiebre/inmunología , Fiebre/patología , Humanos , Inmunidad Celular/efectos de los fármacos , Inmunidad Innata/efectos de los fármacos , Trastornos del Olfato/diagnóstico , Trastornos del Olfato/dietoterapia , Trastornos del Olfato/inmunología , Trastornos del Olfato/patología , Neumonía Viral/diagnóstico , Neumonía Viral/inmunología , Neumonía Viral/patología , Insuficiencia Respiratoria/diagnóstico , Insuficiencia Respiratoria/dietoterapia , Insuficiencia Respiratoria/inmunología , Insuficiencia Respiratoria/patología , SARS-CoV-2 , Índice de Severidad de la Enfermedad , Oligoelementos/uso terapéutico , Vitaminas/uso terapéuticoRESUMEN
Olfactory loss is known to affect both mood and quality of life. Transient anosmia was induced in mice to study the resulting changes in mood, behavior, and on a molecular level. Transient anosmia was induced by a single intranasal instillation of ZnSO4 in BALB/c mice. Hematoxylin and eosin (HE) staining, and potato chip finding test were performed to confirm olfactory loss. Tail suspension, forced swim, and splash tests were performed to evaluate depression-related behavior; while the open field, and elevated plus maze tests were used to evaluate anxiety-related behavior. The mRNA levels of amygdalar corticotropin-releasing hormone (CRH) and hypothalamic glucocorticoid receptor (GR) were quantified using real-time PCR to confirm relevant molecular change. Olfactory loss was confirmed 1-2.5 weeks after induction, and this loss was subsequently reversed over time. The results of the behavioral tests indicated increased depression-like and reduced anxiety-like behavior at week 1. Accordingly, PCR data identified decreased amygdalar CRH expression at week 1. These results suggest that transient anosmia induces both depressive and anxiolytic behavior as a result of decreased amygdalar CRH in a mouse model of anosmia.
Asunto(s)
Conducta Animal/efectos de los fármacos , Hormona Liberadora de Corticotropina/metabolismo , Trastornos del Olfato/patología , Sulfato de Zinc/toxicidad , Administración Intranasal , Amígdala del Cerebelo/metabolismo , Animales , Ansiedad/etiología , Hormona Liberadora de Corticotropina/genética , Depresión/etiología , Modelos Animales de Enfermedad , Hipotálamo/metabolismo , Masculino , Aprendizaje por Laberinto , Ratones , Ratones Endogámicos BALB C , Trastornos del Olfato/inducido químicamente , Trastornos del Olfato/complicaciones , Mucosa Olfatoria/patología , Receptores de Glucocorticoides/genética , Receptores de Glucocorticoides/metabolismoRESUMEN
BACKGROUND: Olfactory loss is highly prevalent, and comorbid mood disorders are common. Considering olfactory input is highly interconnected with the limbic system, and that the limbic system manages mood, it is predictable that impairments in the sense of smell may result in mood changes. METHODOLOGY: Chronic olfactory deficits were induced by repeated intranasal irrigation of ZnSO4 for 12 weeks in BALB/c mice. H&E staining, OMP staining, and potato chip finding test were performed to confirm olfactory loss. Tail suspension, forced swim, and splash tests were performed to evaluate depression, as well as open field, elevated plus maze tests were applied to assess anxiety. The mRNA levels of glucocorticoid receptor (GR) and corticotropin releasing hormone (CRH) were measured by real-time PCR to confirm relevant molecular changes. RESULTS: Disruption of the olfactory epithelium and olfactory loss was confirmed in histological studies and potato chip finding test. Behavioral tests show that the chronic anosmic state caused increased depression and reduced anxiety. PCR data showed that mRNA levels of GR in the hypothalamus and CRH in the amygdala were significantly decreased. CONCLUSIONS: These results propose that ZnSO4-induced chronic anosmia can cause a depressive and anxiolytic state via decreased hypothalamic GR and amygdalar CRH.
Asunto(s)
Amígdala del Cerebelo/metabolismo , Ansiedad/metabolismo , Depresión/etiología , Hipotálamo/metabolismo , Trastornos del Olfato/psicología , Animales , Hormona Liberadora de Corticotropina/metabolismo , Depresión/metabolismo , Modelos Animales de Enfermedad , Masculino , Ratones Endogámicos BALB C , Trastornos del Olfato/metabolismo , Trastornos del Olfato/patología , Mucosa Olfatoria/patología , Distribución Aleatoria , Receptores de Glucocorticoides/metabolismo , Sulfato de ZincRESUMEN
Rising neurodegenerative and depressive disease prevalence combined with the lack of effective pharmaceutical treatments and dangerous side effects, has created an urgent need for the development of effective therapies. Considering that these disorders are multifactorial in origin, treatments designed to interfere at different mechanistic levels may be more effective than the traditional single-targeted pharmacological concepts. To that end, an experimental diet composed of zinc, melatonin, curcumin, piperine, eicosapentaenoic acid (EPA, 20:5, n-3), docosahexaenoic acid (DHA, 22:6, n-3), uridine, and choline was formulated. This diet was tested on the olfactory bulbectomized rat (OBX), an established animal model of depression and cognitive decline. The ingredients of the diet have been individually shown to attenuate glutamate excitoxicity, exert potent anti-oxidant/anti-inflammatory properties, and improve synaptogenesis; processes that all have been implicated in neurodegenerative diseases and in the cognitive deficits following OBX in rodents. Dietary treatment started 2 weeks before OBX surgery, continuing for 6 weeks in total. The diet attenuated OBX-induced cognitive and behavioral deficits, except long-term spatial memory. Ameliorating effects of the diet extended to the control animals. Furthermore, the experimental diet reduced hippocampal atrophy and decreased the peripheral immune activation in the OBX rats. The ameliorating effects of the diet on the OBX-induced changes were comparable to those of the NMDA receptor antagonist, memantine, a drug used for the management of Alzheimer's disease. This proof-of-concept study suggests that a diet, which simultaneously targets multiple disease etiologies, can prevent/impede the development of a neurodegenerative and depressive disorders and the concomitant cognitive deficits.
Asunto(s)
Trastornos del Conocimiento/dietoterapia , Trastornos del Conocimiento/tratamiento farmacológico , Memantina/uso terapéutico , Enfermedades Neurodegenerativas/dietoterapia , Enfermedades Neurodegenerativas/tratamiento farmacológico , Nootrópicos/uso terapéutico , Animales , Atrofia/dietoterapia , Atrofia/tratamiento farmacológico , Atrofia/patología , Atrofia/fisiopatología , Muerte Celular/efectos de los fármacos , Muerte Celular/fisiología , Trastornos del Conocimiento/patología , Trastornos del Conocimiento/fisiopatología , Trastorno Depresivo , Modelos Animales de Enfermedad , Hipocampo/efectos de los fármacos , Hipocampo/patología , Hipocampo/fisiopatología , Masculino , Trastornos de la Memoria/dietoterapia , Trastornos de la Memoria/tratamiento farmacológico , Trastornos de la Memoria/patología , Trastornos de la Memoria/fisiopatología , Enfermedades Neurodegenerativas/patología , Enfermedades Neurodegenerativas/fisiopatología , Neuroinmunomodulación/efectos de los fármacos , Neuroinmunomodulación/fisiología , Fármacos Neuroprotectores/uso terapéutico , Trastornos del Olfato/patología , Trastornos del Olfato/fisiopatología , Bulbo Olfatorio/fisiopatología , Agitación Psicomotora/dietoterapia , Agitación Psicomotora/tratamiento farmacológico , Agitación Psicomotora/patología , Agitación Psicomotora/fisiopatología , Ratas , Ratas Sprague-Dawley , Percepción Espacial/efectos de los fármacos , Percepción Espacial/fisiología , Sulfato de ZincRESUMEN
Olfactory information reaches olfactory cortex without a thalamic relay. This neuroanatomical substrate has combined with functional findings to suggest that, in olfaction, the typical thalamic role in sensory processing has shifted to the olfactory bulb or olfactory cortex. With this in mind, we set out to ask whether the thalamus at all plays a significant functional role in human olfaction. We tested olfactory function in 17 patients with unilateral focal thalamic lesions and in age-matched healthy controls. We found that thalamic lesions did not significantly influence olfactory detection but significantly impaired olfactory identification, and only right lesions altered olfactory hedonics by reducing the pleasantness of pleasant odors. An auditory control revealed that this shift in pleasantness was olfactory specific. These olfactory impairments were evident in explicit measures of perception, as well as in patterns of sniffing. Whereas healthy subjects modulated their sniffs in accordance with odorant content, thalamic patients did not. We conclude that, although the thalamus is not in the path of olfactory information from periphery to cortex, it nevertheless plays a significant functional role in human olfaction.
Asunto(s)
Trastornos del Olfato/etiología , Trastornos del Olfato/patología , Olfato/fisiología , Tálamo/patología , Estimulación Acústica/métodos , Adulto , Anciano , Mapeo Encefálico/métodos , Trastornos Cerebrovasculares/complicaciones , Trastornos Cerebrovasculares/patología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Odorantes , Umbral Sensorial/fisiología , Tálamo/fisiologíaRESUMEN
Odor is the only sensation thought to be unrelated to the thalamus. However, accumulating evidence suggests that the dorsomedial nucleus (DM) of the thalamus is associated with odor. Although the thalamus is prone to ischemia, only a single patient with bilateral DM infarctions was reported to have odor abnormalities. We describe a second such patient with infarctions involving the left DM and the right ventral posterior nucleus and ventral lateral nucleus, nuclei adjacent to the DM, associated with transient edema. In contrast to the previous case, our patient had transient odor abnormality. These observations suggested that direct and/or indirect bilateral involvement of the DM might be associated with odor abnormalities in patients with thalamic infarction.
Asunto(s)
Infarto Encefálico/complicaciones , Trastornos del Olfato/etiología , Vías Olfatorias/fisiopatología , Trastornos del Gusto/etiología , Tálamo/irrigación sanguínea , Anciano , Infarto Encefálico/diagnóstico , Infarto Encefálico/patología , Lateralidad Funcional , Humanos , Imagen por Resonancia Magnética , Masculino , Trastornos del Olfato/patología , Vías Olfatorias/patología , Trastornos del Gusto/patología , Tálamo/patologíaRESUMEN
Irritation and negative valence are closely associated in perception. However, these perceptual aspects can be dissociated in olfaction where irritation can accompany both pleasant and unpleasant odorants. Whereas the sensation of odor reflects transduction at olfactory receptors, irritation reflects concurrent transduction of the odorant at trigeminal receptors. Thus a stimulus can be either a pure olfactant activating the olfactory receptors only or a bimodal odorant activating both types of receptors. Using event-related functional magnetic resonance imaging and a 2 x 2 experimental design contrasting odorant valence (pleasant/unpleasant) and odorant type (pure olfactant/bimodal) we found activity in piriform cortex to be associated with valence, and not type, of odors. In contrast, activity in the olfactory tubercle was associated with type, and not valence, of odors. Importantly, this was found when perceived intensity was held equal across odorants. These findings suggest that dissociable neural substrates subserve the encoding of irritation and valence in olfaction.